Vogenx
CompanyUnited StatesFounded 2021
Vogenx develops one asset, in phase 2 (Mizagliflozin in postbariatric hypoglycemia). Mostly small molecule; based in the United States, founded in 2021.
- 1
- Asset
- Furthest stage
- Phase 2
- Raised
- $81M
- 2
- Trials
- 4
- Signals
Pipeline
1Inhibits intestinal SGLT1 to reduce glucose absorption and blunt postprandial glucose excursions.
Phase 2, Small molecule, postbariatric hypoglycemia
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials2
- Funding rounds and grants1
- Deals1
- People6
- Signals7